On Wednesday 10 February, the European Commission accepted the commitments offered by Aspen to reduce the prices it charges in Europe for six essential off-patent cancer medicines by an average of 73%. In addition, this global pharmaceutical company, headquartered in South Africa, has to guarantee the continued supply of these medicines, whose patents have expired, for a significant period.
“These commitments remove entirely the Commission’s concerns of excessive pricing in breach of EU...